Logo

About Erleada


Mechanism of action

ERLEADA® was designed to selectively and irreversibly bind to the androgen receptor (AR) and thus inhibit AR signaling at various locations:[1]

Watch this 1 minute video to discover the mode of action of Erleada.

Mechanism of action

ERLEADA® has no agonistic effect on the AR.

Dosage & administration
0
Packaging
0
Contraindications

The use of Erleada® is contraindicated in the following cases[2]:

0
Side effects


Summary of the undesirable effects


The most common side effects are fatigue (26%), rash (26% all grades together and 6% grade 3 or 4), hypertension (22%), hot flushes (18%), arthralgia (17%), diarrhea (16%), falls (13%) and weight loss (13%). Other significant side effects include fractures (11%) and hypothyroidism (8%).[2]

Undesirable effects identified in clinical studies


System organ class

Adverse reaction & frequency

System organ class

Endocrine disorders 

Adverse reaction & frequency

Common: hypothyroidisma

System organ class

Metabolism and nutrition disorders 

Adverse reaction & frequency

Very common: decreased appetite 
Common: hypercholesterolemia, hypertriglyceridemia

System organ class

Nervous system disorders 

Adverse reaction & frequency

Common: dysgeusia
Uncommon: seizureb

System organ class

Cardiac disorders 

Adverse reaction & frequency

Common: ischemic heart diseasec

Not known: QT prolongation

System organ class

Vascular disorders

Adverse reaction & frequency

Very common: hot flush, hypertension

System organ class

Gastrointestinal disorders

Adverse reaction & frequency

Very common: diarrhoea

System organ class

Skin and subcutaneous tissue disorders

Adverse reaction & frequency

Very common: skin rashd
Common: pruritus
Not known: toxic epidermal necrolysise

System organ class

Musculoskeletal and connective tissue disorders

Adverse reaction & frequency

Very common: fracturef, arthralgia
Common: muscle spasm

System organ class

General disorders and administration site conditions

Adverse reaction & frequency

Very common: fatigue

System organ class

Investigations

Adverse reaction & frequency

Very common: weight decreased

System organ class

Injury, poisoning and procedural complications

Adverse reaction & frequency

Very common: fall

a Includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine decreased, autoimmune thyroiditis, thyroxine free decreased, tri-iodothyronine decreased 

b Includes tongue biting 

c Includes angina pectoris, angina unstable, myocardial infarction, acute myocardial infarction, coronary artery occlusion, coronary artery stenosis, acute coronary syndrome, arteriosclerosis coronary artery, cardiac stress test abnormal, troponin increased, myocardial ischaemia 

d See “Skin rash” under “Description of selected adverse reactions” 

e Post-marketing adverse reaction 

f Includes rib fracture, lumbar vertebral fracture, spinal compression fracture, spinal fracture, foot fracture, hip fracture, humerus fracture, thoracic vertebral fracture, upper limb fracture, fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle fracture, compression fracture, costal cartilage fracture, facial bones fracture, lower limb fracture, osteoporotic fracture, wrist fracture, avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, radius fracture, sternal fracture, stress fracture, traumatic fracture, cervical vertebral fracture, femoral neck fracture, tibia fracture.

SmPC
You can consult the summary of the product characteristics of Erleada here.
0

Video

Learn more on Erleada (apalutamide) via this dynamic, interactive video on:

  • The mode of action
  • The dosing and administration
  • The registration trials SPARTAN (nmCRPC) and TITAN (mHSPC)
Contact banner

GnRH = gonadotropin-releasing hormone

AR = androgen receptor

DNA = deoxyribonucleic acid

° The active substance in this medicine is apalutamide. Each film-coated tablet contains 60 mg of apalutamide. The other ingredients in the tablet core of this medicine are colloidal anhydrous silica, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose and silicified microcrystalline cellulose. The film coating contains black iron oxide (E172), yellow iron oxide (E172), macrogol, polyvinyl alcohol (partially hydrolyzed), talc and titanium dioxide (E171).

Erleada is indicated:1

  • for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in adult men, in combination with androgen deprivation therapy (ADT)
  • for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men with a high risk of developing metastatic disease in combination with ADT

Erleada is reimbursed as of the 1st of September 2021 in Belgium. Price ex-factory excl. VAT: €2952,56

Erleada is reimbursed as of the 1st of July 2020 in Luxembourg. Public Price: € 3114,65


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section “Undesirable effects” for how to report adverse reactions.

CP-231367 - May 2021